Long-acting injectable antipsychotics: Shall the last be first?

CNS Spectrums

Volumn 19, Issue 1, 2014, Pages 3-5

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LONG ACTING DRUG; NEUROLEPTIC AGENT;

ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG FORMULATION; DRUG RESPONSE; GRAY MATTER; HOSPITAL READMISSION; HUMAN; MENTAL HEALTH CARE; POLYPHARMACY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; COMORBIDITY; DISEASE COURSE; DRUG USE; EARLY INTERVENTION; HOSPITALIZATION; INJECTION; REVIEW; THERAPY DELAY; TREATMENT PLANNING;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; SCHIZOPHRENIA;

EID: 84896735572     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913001016     Document Type: Article

References (14)

1. Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 5th ed. Cambridge, UK: Cambridge University Press; 2014.
2. Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13(7):767-783.
3. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
4. Shi L, Ascher-Svanum H, Zhu B, et al. Characteristics and use patterns of patients taking first generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4):482-488.
5. Munk-Jorgensen P, Nielsen J, Nielsen RE, Stahl SM. Last episode psychosis. Acta Psychiatr Scand. 2009;119(6):417-418.
6. Morrisette DA, Stahl SM. Optimizing outcomes in schizophrenia: long acting depots and long term treatment. CNS Spectr. 2012;17(Suppl 1):10-21.
7. Morrissette DA, Stahl SM. Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In: Ritsner MS, ed. Polypharmacy in Psychiatric Practice. Dordrecht, NL: Springer. Vol. I; 2012:107-125.
8. Van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;32(10):2057-2066.
9. Stahl SM. Stahl;s Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.
10. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439-1444.
11. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957-965.
12. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609.
13. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 2011;364(9):842-851.
14. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011;168(3):286-292.